Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00228150
Recruitment Status : Completed
First Posted : September 28, 2005
Last Update Posted : December 23, 2008
Information provided by:

Brief Summary:
The primary objective is to assess the effect of SR57667B at the dose of 4 mg/d on the progression of Parkinson symptoms in patients with early PD. The primary outcome will be the time to progression of disability warranting initiation of L-dopa or a dopamine agonist. Secondary outcomes will comprise assessments of symptoms, activities of daily living and global clinical status.

Condition or disease Intervention/treatment Phase
Parkinson Disease Drug: SR57667B Phase 2

Detailed Description:
Multinational, multicenter, randomized, parallel-group, double-blind, phase II study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 564 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety and Tolerability Study of SR57667B in Outpatients With Early Parkinson's Disease
Study Start Date : July 2003
Actual Primary Completion Date : April 2006
Actual Study Completion Date : April 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Time to disability warranting introduction of Ldopaor a dopamine agonist.

Secondary Outcome Measures :
  1. Unified Parkinson's Disease Rating Scale (UPDRS)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female outpatients.
  • Age >=35 years at screening.·
  • Diagnosis of Parkinson's syndrome, on at least two of the three key Parkinson's symptoms, i.e. resting tremor, bradykinesia and rigidity.
  • Duration of the disease of less than 3 years since diagnosis·
  • Modified Hoehn and Yahr stage <= 2.5.
  • Untreated patients.
  • Generally healthy and ambulatory.
  • Patient has given his informed written consent and is capable of following study procedures.

Exclusion Criteria:

  • Any indication of forms of parkinsonism other than PD.
  • Severe resting tremor.
  • Presence of either dyskinesia, fluctuations, or loss of postural reflexes·
  • Treatment with L-Dopa, dopamine agonist, amantadine, anticholinergics, catechol-o-methyltransferase (COMT ) inhibitors, selegiline, dopamine receptor antagonists, catecholamine depleters, indirect dopamine agonists or alphamethyldopa.
  • Electroconvulsive therapy (ECT).
  • Use of CYP3A4 strong, and moderate inducers or inhibitors.
  • Participation in another clinical trial with an investigational drug within two months prior to randomization.
  • Dementia, uncontrolled depression, psychotic disorder.
  • History of substance-related disorders including alcohol or other substance use disorders.
  • Females of child bearing potential.
  • Evidence (detected by history, physical examination and/or laboratory/ECG tests) of any clinically significant or unstable medical disorder that could interfere with the patient's participation in the clinical trial; interfere with the absorption, metabolism or excretion of the study medication; or interfere with the evaluation of the study drug.
  • Alterations of laboratory tests or ECG findings of potential clinical significance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00228150

Layout table for location information
Sanofi-Aventis Administrative Office
Wien, Austria
Sanofi-Aventis Administrative Office
Laval, Canada
Sanofi-Aventis Administrative Office
Horsholm, Denmark
Sanofi-Aventis Administrative Office
Paris, France
Sanofi-Aventis Administrative Office
Berlin, Germany
Sanofi-Aventis Administrative Office
Casablanca, Morocco
Sanofi-Aventis Administrative Office
Gouda, Netherlands
Sanofi-Aventis Administrative Office
Porto Salvo, Portugal
South Africa
Sanofi-Aventis Administrative Office
Midrand, South Africa
Sanofi-Aventis Administrative Office
Barcelona, Spain
Sanofi-Aventis Administrative Office
Bromma, Sweden
Sanofi-Aventis Administrative Office
Megrine, Tunisia
United Kingdom
Sanofi-Aventis Administrative Office
Guilford Surrey, United Kingdom
Sponsors and Collaborators
Layout table for investigator information
Study Chair: Mark GUTMAN, MD Scientific Advisory Committee
Study Chair: Werner POEWE, MD Scientific Advisory Committee
Study Chair: Olivier RASCOL, MD Scientific Advisory Committee
Study Chair: Eduardo TOLOSA, MD Scientific Advisory Committee

Additional Information:
Layout table for additonal information
Responsible Party: ICD Study Director, sanofi-aventis Identifier: NCT00228150    
Other Study ID Numbers: EFC5287
First Posted: September 28, 2005    Key Record Dates
Last Update Posted: December 23, 2008
Last Verified: December 2008
Keywords provided by Sanofi:
Parkinson Disease
dopamine agonists
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases